NO173446C - Analogifremgangsmaate til fremstilling av nye, terapeutisk aktive, substituerte alkandifosfonsyrer - Google Patents

Analogifremgangsmaate til fremstilling av nye, terapeutisk aktive, substituerte alkandifosfonsyrer

Info

Publication number
NO173446C
NO173446C NO874856A NO874856A NO173446C NO 173446 C NO173446 C NO 173446C NO 874856 A NO874856 A NO 874856A NO 874856 A NO874856 A NO 874856A NO 173446 C NO173446 C NO 173446C
Authority
NO
Norway
Prior art keywords
substituted
acids
halogen
phosphono group
alkandiphosphonic
Prior art date
Application number
NO874856A
Other languages
English (en)
Norwegian (no)
Other versions
NO874856D0 (no
NO173446B (no
NO874856L (no
Inventor
Knut A Jaeggi
Leo Widler
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4280350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO173446(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO874856D0 publication Critical patent/NO874856D0/no
Publication of NO874856L publication Critical patent/NO874856L/no
Publication of NO173446B publication Critical patent/NO173446B/no
Publication of NO173446C publication Critical patent/NO173446C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Control Of El Displays (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Glass Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO874856A 1986-11-21 1987-11-20 Analogifremgangsmaate til fremstilling av nye, terapeutisk aktive, substituerte alkandifosfonsyrer NO173446C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH466686 1986-11-21

Publications (4)

Publication Number Publication Date
NO874856D0 NO874856D0 (no) 1987-11-20
NO874856L NO874856L (no) 1988-05-24
NO173446B NO173446B (no) 1993-09-06
NO173446C true NO173446C (no) 1993-12-15

Family

ID=4280350

Family Applications (2)

Application Number Title Priority Date Filing Date
NO874856A NO173446C (no) 1986-11-21 1987-11-20 Analogifremgangsmaate til fremstilling av nye, terapeutisk aktive, substituerte alkandifosfonsyrer
NO2001015C NO2001015I2 (no) 1986-11-21 2001-09-04 Zoledronsyre

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2001015C NO2001015I2 (no) 1986-11-21 2001-09-04 Zoledronsyre

Country Status (27)

Country Link
US (1) US4939130A (el)
EP (1) EP0275821B1 (el)
JP (1) JP2744238B2 (el)
KR (1) KR960010752B1 (el)
AT (1) ATE72816T1 (el)
AU (1) AU607722B2 (el)
CA (1) CA1338937C (el)
CY (1) CY1827A (el)
DD (1) DD270533A5 (el)
DE (2) DE3776880D1 (el)
DK (1) DK174098B1 (el)
ES (1) ES2038692T4 (el)
FI (1) FI87570C (el)
GR (1) GR3003895T3 (el)
HK (1) HK114894A (el)
HU (1) HU199150B (el)
IE (1) IE59816B1 (el)
IL (1) IL84497A (el)
LU (1) LU90838I2 (el)
MX (1) MX9427A (el)
NL (1) NL300058I2 (el)
NO (2) NO173446C (el)
NZ (1) NZ222610A (el)
PH (1) PH24345A (el)
PT (1) PT86167B (el)
SG (1) SG92194G (el)
ZA (1) ZA878698B (el)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3640938A1 (de) * 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
US5139786A (en) * 1989-07-07 1992-08-18 Ciba-Geigy Corporation Topical formulations
JPH06507156A (ja) * 1991-04-27 1994-08-11 日本チバガイギー株式会社 トリアゾール化合物
US5763611A (en) * 1992-05-29 1998-06-09 The Procter & Gamble Company Thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
US5391743A (en) * 1992-05-29 1995-02-21 Procter & Gamble Pharmaceuticals, Inc. Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
EP0646119B1 (en) * 1992-05-29 1998-07-15 PROCTER & GAMBLE PHARMACEUTICALS, INC. Quaternary nitrogen-containing phosphonate compounds for treating abnormal calcium and phosphate metabolism as well as dental calculus and plaque
CA2136818C (en) * 1992-05-29 2000-01-18 Susan M. Kaas Sulfur-containing phosphonate compounds for treating abnormal calcium and phosphate metabolism
US5753634A (en) * 1992-05-29 1998-05-19 The Procter & Gamble Company Quaternary nitrogen containing phosphonate compounds, pharmaceutical compostions, and methods for treating abnormal calcium and phosphate metabolism
WO1993024500A1 (en) * 1992-05-29 1993-12-09 The Procter & Gamble Pharmaceuticals, Inc. Thio-substituted nitrogen-containing heterocyclic phosphonate compounds for treating abnormal calcium and phosphate metabolism
RU2119794C1 (ru) * 1992-06-30 1998-10-10 Проктер энд Гэмбл Фармасьютикалз, Инк. Использование фосфонатов и нестероидных противовоспалительных лекарственных средств для лечения артрита, способ лечения
AU670337B2 (en) 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
US5880111A (en) * 1995-06-07 1999-03-09 Farcasiu; Dan Therapeutic derivations of diphosphonates
IL115041A0 (en) * 1995-08-23 1995-12-08 Yissum Res Dev Co Novel bisphosphonates process for their preparation and pharmaceutical compositions containing them
JPH11513383A (ja) * 1995-09-29 1999-11-16 ノバルティス アクチェンゲゼルシャフト ウマの舟状骨病を治療する方法
US6284748B1 (en) * 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
ES2210728T3 (es) * 1997-03-07 2004-07-01 Metabasis Therapeutics, Inc. Nuevos inhibidores bencimidazol de la fructosa-1, 6-bifosfatasa.
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
PT1112275E (pt) * 1998-09-09 2003-12-31 Metabasis Therapeutics Inc Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
KR100875335B1 (ko) * 1999-12-22 2008-12-22 메타베이시스 테라퓨틱스, 인크. 신규 비스아미데이트 포스포네이트 프로드러그
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
PE20011061A1 (es) 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
RU2288722C2 (ru) 2000-06-20 2006-12-10 Новартис Аг Способ введения бисфосфонатов
CZ301972B6 (cs) * 2000-06-20 2010-08-18 Novartis Ag Farmaceutické prostredky s obsahem kyseliny zoledronové pro lécení stavu s abnormálne zvýšeným kostním obratem
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
PL368068A1 (en) 2001-05-16 2005-03-21 Novartis Ag Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
US20060069067A1 (en) * 2002-07-30 2006-03-30 Bhatnagar Ajay S Combination of an aromatase inhibitor with a bisphosphonate
EP1546110A4 (en) * 2002-07-30 2008-03-26 Univ Virginia ACTIVE COMPOUNDS IN THE SIGNALING OF SPHINGOSINE 1-PHOSPHATE
CA2497353C (en) * 2002-09-16 2012-08-28 Novartis Ag Method for preventing or reducing secondary fractures after hip fracture
ES2530791T3 (es) * 2002-12-20 2015-03-05 Hoffmann La Roche Formulación de ibandronato de altas dosis
EP1525207A2 (en) * 2003-02-27 2005-04-27 Teva Pharmaceutical Industries Limited Process for purification of zoledronic acid
ES2322592T3 (es) 2003-07-03 2009-06-23 Teva Pharmaceutical Industries Ltd. Formas cristalinas de acido zoledronico, formas cristlinas de la sal sodica de zoledronato, sal sodica de zoledronato amorfa y procedimientos para su preparacion.
US20050049693A1 (en) * 2003-08-25 2005-03-03 Medtronic Vascular Inc. Medical devices and compositions for delivering biophosphonates to anatomical sites at risk for vascular disease
MY141763A (en) * 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
US20050119230A1 (en) * 2003-09-18 2005-06-02 Alexandra Glausch Pharmaceutical products comprising bisphosphonated
NZ545804A (en) * 2003-09-19 2009-09-25 Wisconsin Alumni Res Found Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
US7638637B2 (en) * 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
EP1716161B1 (en) * 2003-12-23 2011-05-04 Alchymars S.p.A. Ibandronic acid monosodium salt in the amorphous form
WO2005063717A1 (en) * 2003-12-26 2005-07-14 Natco Pharma Limited An improved process for the preparation of zoledronic acid
JP2008510018A (ja) * 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規チアゾール阻害物質
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
EP1802641B8 (en) * 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
EP1827606A2 (en) * 2004-12-06 2007-09-05 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
WO2006062072A1 (ja) * 2004-12-10 2006-06-15 Tmrc Co., Ltd. 転移癌治療剤および癌転移抑制剤
US7754703B2 (en) * 2005-02-14 2010-07-13 University Of Virginia Patent Foundation Cycloalkane-containing sphingosine 1-phosphate agonists
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
WO2006100687A1 (en) * 2005-03-24 2006-09-28 Dabur Pharma Ltd. Disodium pamidronate aqueous formulation
WO2006134603A1 (en) * 2005-06-13 2006-12-21 Jubilant Organosys Limited Process for producing bisphosphonic acids and forms thereof
AR054673A1 (es) * 2005-07-28 2007-07-11 Gador Sa Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende
WO2007032808A1 (en) * 2005-09-12 2007-03-22 Dr. Reddy's Laboratories Ltd. Crystalline trihydrate of zoledronic acid
AU2007209961A1 (en) * 2006-01-27 2007-08-09 University Of Virginia Patent Foundation Method for treatment of neuropathic pain
WO2007092638A1 (en) * 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
CA2646334A1 (en) * 2006-03-17 2007-09-27 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
WO2007125521A2 (en) * 2006-05-02 2007-11-08 Ranbaxy Laboratories Limited Polymorphic form of zoledronic acid and processes for their preparation
WO2008064315A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
WO2008064320A2 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
AU2007323557A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
US20100144679A1 (en) * 2007-03-21 2010-06-10 Duke University Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
US20090082312A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched zoledronic acid
ITPA20070034A1 (it) * 2007-10-30 2009-04-30 Tetrapharm S R L Bifosfonati geminali, loro preparazione e loro impiego in campo oncologico.
US7977323B2 (en) 2007-11-30 2011-07-12 Novartis Ag C2-C5-alkyl-imidazole-bisphosphonates
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
EA201001578A1 (ru) * 2008-04-04 2011-06-30 Новартис Аг Фармацевтическая композиция с бисфосфонатом
PL213599B1 (pl) 2008-10-31 2013-03-29 Politechnika Gdanska Sposób otrzymywania kwasu [1-hydroksy-2-(1H-imidazol-1-ilo)-etylideno] bisfosfonowego
US20100130746A1 (en) * 2008-11-26 2010-05-27 Martin Kas Process for Making Zoledronic Acid
EP2192126B1 (en) 2008-11-26 2013-03-27 Synthon B.V. Process for making zoledronic acid
KR20110110219A (ko) * 2008-12-23 2011-10-06 노파르티스 아게 페닐알킬-이미다졸-비스포스포네이트 화합물
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
AU2010278860B2 (en) 2009-07-31 2016-05-26 Thar Pharma, Llc Crystallization method and bioavailability
US8980868B2 (en) 2009-07-31 2015-03-17 Thar Pharmaceuticals, Inc. Oral forms of a phosphonic acid derivative
PT2473172E (pt) 2009-09-01 2015-06-25 Univ Duke Composições de bisfosfonato e métodos para o tratamento de insuficiência cardíaca
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
US20130138221A1 (en) 2010-04-16 2013-05-30 Novartis Ag Methods and compositions for improving implant osseointegration
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
HU230718B1 (hu) 2011-02-08 2017-11-28 Richter Gedeon Nyrt. Új eljárás dronsavak gyógyszeripari előállítására
CN102276650A (zh) * 2011-06-22 2011-12-14 苏州莱克施德药业有限公司 一种唑来膦酸的制备方法
WO2013074587A1 (en) 2011-11-16 2013-05-23 Duke University Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction
CN102617642B (zh) * 2012-02-24 2015-11-18 江苏省原子医学研究所 一种含2-乙基咪唑的双膦酸化合物及其制备方法和应用
CN102659840B (zh) * 2012-05-10 2013-08-14 苏州普瑞诺药物技术有限公司 咪唑双膦酸类化合物及其可药用盐及药物用途
US9925203B2 (en) 2012-05-14 2018-03-27 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9895383B2 (en) 2012-05-14 2018-02-20 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9867839B2 (en) 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9782421B1 (en) 2012-05-14 2017-10-10 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US10039773B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating arthritis
US9655908B2 (en) 2012-05-14 2017-05-23 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9867840B2 (en) 2014-05-27 2018-01-16 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9427403B2 (en) 2012-05-14 2016-08-30 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9877977B2 (en) 2012-05-14 2018-01-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9707247B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9662343B2 (en) 2012-05-14 2017-05-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9844559B2 (en) 2012-05-14 2017-12-19 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesions
US9827256B2 (en) 2014-05-27 2017-11-28 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US9707245B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10028908B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9999628B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9289441B2 (en) 2014-08-08 2016-03-22 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10080765B2 (en) 2012-05-14 2018-09-25 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10111837B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds
US10034890B2 (en) 2012-05-14 2018-07-31 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9717747B2 (en) 2012-05-14 2017-08-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US10028969B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9820999B2 (en) 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9211257B2 (en) 2012-05-14 2015-12-15 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10016446B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US10092581B2 (en) 2014-05-15 2018-10-09 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9901589B2 (en) 2012-05-14 2018-02-27 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9694023B2 (en) 2012-05-14 2017-07-04 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9675626B2 (en) 2012-05-14 2017-06-13 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9669040B2 (en) 2012-05-14 2017-06-06 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9795622B2 (en) 2012-05-14 2017-10-24 Antecip Bioventures Ii Llc Neridronic acid for treating pain associated with a joint
US8865757B1 (en) 2014-05-28 2014-10-21 Antecip Bioventures Ii Llp Therapeutic compositions comprising imidazole and imidazolium compounds
US9770457B2 (en) 2012-05-14 2017-09-26 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesion
US10173986B2 (en) 2012-05-14 2019-01-08 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US10004756B2 (en) 2014-05-15 2018-06-26 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9943531B2 (en) 2014-08-08 2018-04-17 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9789128B2 (en) 2012-05-14 2017-10-17 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9827192B2 (en) 2012-05-14 2017-11-28 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9616078B2 (en) 2012-05-14 2017-04-11 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9956237B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9949993B2 (en) 2012-05-14 2018-04-24 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9700570B2 (en) 2014-05-27 2017-07-11 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US8802658B2 (en) 2012-05-14 2014-08-12 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9861648B2 (en) 2012-05-14 2018-01-09 Antecip Boiventures Ii Llc Osteoclast inhibitors for knee conditions
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US9956234B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9012432B2 (en) 2013-03-08 2015-04-21 Levolta Pharmaceuticals, Inc. Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
CN114404427A (zh) 2014-02-13 2022-04-29 配体药物公司 前药化合物及其用途
US9127069B1 (en) 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
RU2725962C2 (ru) * 2020-02-12 2020-07-07 Акционерное Общество "Фарм-Синтез" Способ приготовления фармацевтической композиции на основе золедроновой кислоты в виде раствора для инфузий для лечения онкологических заболеваний и способ получения фармацевтической композиции на основе золедроновой кислоты в виде концентрата для приготовления раствора для инфузий для лечения онкологических заболеваний
CN114057648B (zh) * 2020-07-30 2024-02-20 常州方圆制药有限公司 一种唑来膦酸中间体杂质的制备方法
KR20220115062A (ko) 2021-02-09 2022-08-17 (주)오스티오뉴로젠 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3203308A1 (de) * 1982-01-27 1983-07-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Diphosphonsaeure-derivate und diese enthaltende pharmazeutische praeparate
DE3203307A1 (de) * 1982-01-27 1983-07-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Phosphonate, und diese enthaltende pharmazeutische verbindungen
EP0084822B1 (de) * 1982-01-27 1986-01-08 Schering Aktiengesellschaft Diphosphonsäure-Derivate und diese enthaltende pharmazeutische Präparate
DE3428524A1 (de) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel

Also Published As

Publication number Publication date
NL300058I1 (nl) 2001-12-01
JPS63150291A (ja) 1988-06-22
KR960010752B1 (ko) 1996-08-08
LU90838I2 (fr) 2001-11-19
GR3003895T3 (el) 1993-03-16
FI87570B (fi) 1992-10-15
DK174098B1 (da) 2002-06-17
IL84497A0 (en) 1988-04-29
NZ222610A (en) 1990-09-26
EP0275821A1 (de) 1988-07-27
SG92194G (en) 1995-04-28
PH24345A (en) 1990-06-13
ATE72816T1 (de) 1992-03-15
IL84497A (en) 1994-10-21
ZA878698B (en) 1988-05-23
FI87570C (fi) 1993-01-25
PT86167A (en) 1987-12-01
DD270533A5 (de) 1989-08-02
HK114894A (en) 1994-10-27
NO874856D0 (no) 1987-11-20
DK609587A (da) 1988-05-22
FI875096A (fi) 1988-05-22
CY1827A (en) 1995-12-01
KR880006204A (ko) 1988-07-22
HU199150B (en) 1990-01-29
AU8145387A (en) 1988-05-26
AU607722B2 (en) 1991-03-14
JP2744238B2 (ja) 1998-04-28
DK609587D0 (da) 1987-11-20
NO2001015I2 (no) 2004-10-11
US4939130A (en) 1990-07-03
ES2038692T4 (es) 2012-02-10
DE3776880D1 (de) 1992-04-02
PT86167B (pt) 1990-08-31
EP0275821B1 (de) 1992-02-26
IE59816B1 (en) 1994-04-06
DE10199052I1 (de) 2002-01-10
HUT46330A (en) 1988-10-28
FI875096A0 (fi) 1987-11-18
ES2038692T3 (es) 1993-08-01
CA1338937C (en) 1997-02-25
MX9427A (es) 1993-12-01
NO173446B (no) 1993-09-06
NO874856L (no) 1988-05-24
NL300058I2 (nl) 2002-02-01
IE873148L (en) 1988-05-21

Similar Documents

Publication Publication Date Title
NO173446C (no) Analogifremgangsmaate til fremstilling av nye, terapeutisk aktive, substituerte alkandifosfonsyrer
ES2054826T3 (es) Peptidos con actividad inhibidora de colagenasa.
DE3363593D1 (en) 2-nitro-ethene diamines, process for their preparation and their use as medicines
MY103191A (en) Novel substituted aminomethanediphosphonic acids

Legal Events

Date Code Title Description
SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: ZOLEDRONSYRE OG SALTER DERAV; NAT. REG. NO/DATE: NO , 00/393 20010607; FIRST REG. NO/DATE: CH , 55463 20001128

Spc suppl protection certif: 2001015

Filing date: 20010904

Extension date: 20121120

MK1K Patent expired
SPCX Expiry of an spc

Free format text: PRODUCT NAME: ZOLEDRONSYRE OG SALTER DERAV; NAT. REG. NO/DATE: NO , 00/393 20010607; FIRST REG. NO/DATE: CH , 55463 20001128

Spc suppl protection certif: 2001015